

1 **Effects of a lifestyle program on vascular reactivity in macro and microcirculation**

2 **in severely obese adolescents**

3 David Montero ^{1,3}, MSc; Guillaume Walther ¹, PhD; Antonia Perez-Martin ², MD, PhD; Charles S Mercier
4 ⁴, MD, PhD; Sandrine Gayrard ¹, MSc; Nestor Vicente-Salar ³, PhD; Jose M Sempere ⁶, PhD; Pascual
5 Martinez-Peinado ⁶, MSc; Enrique Roche ^{3,5}, PhD; Agnès Vinet ¹, PhD

6
7 1)Avignon University, LAPEC EA4278, F-84000, Avignon, France, 2) Vascular Medicine Unit,
8 Nimes University Hospital, Nimes, France, 3)Applied Biology Department – Nutrition/Institute
9 of Bioengineering, University Miguel Hernandez, Elche (Alicante), Spain, 4) AJO® les Oiseaux,
10 Sanary/Mer, France, 5)CIBERobn (Fisiopatología de la Obesidad y la Nutrición CB12/03/30038).
11 Instituto de Salud Carlos III, Spain, 6) Unit of Immunology. Depàrtment of Biotechnology.
12 University of Alicante (San Vicente del Raspeig), Spain

13
14 Abbreviated title: Vascular reactivity in obese adolescents

15 Keywords: endothelial function – vascular smooth muscle– adolescent – macrocirculation -
16 microcirculation

17 Word count: 3412; number of tables: 4

18 Clinical Trial Registration: ISRCTN99414527, www.ISRCTN.org

19
20 Corresponding and reprinting requests author: A Vinet, Avignon University ,Faculty of Science, LAPEC
21 EA4278, 33 rue Louis Pasteur, F- 84000 Avignon - France, +334 90 16 29 31, + 334 90 16 29 01 (fax),
22 France. E-mail: agnes.vinet@univ-avignon.fr

23
24 This study was supported by grants from the French Society of Vascular Medicine 2010-2012 (to A.V.
25 and A.P.M), and the Spanish Ministry of Health (CIBERobn CB12/03/30038) (to E.R.)

26 DISCLOSURE STATEMENT: The authors have nothing to disclose

27 ABSTRACT

28 **Context and Objective:** This study aimed to comprehensively assess the macro- and microcirculation of
29 severely obese adolescents (SOA) and normal-weight counterparts, and determine the longitudinal effects
30 of weight loss on vascular function in SOA.

31 **Design, Setting, Participants, and Outcome Measures:** Seventeen SOA (BMI z-score = 4.22 ± 0.73)
32 before and after a 4-month weight loss program, and nineteen puberty-matched normal-weight
33 counterparts (BMI z-score = -0.02 ± 1.04) were studied. Brachial artery flow-mediated dilation (FMD)
34 and response to sublingual nitrate (NMD) were assessed by high-resolution ultrasound. Microvascular
35 reactivity was evaluated by laser Doppler flowmetry in response to NMD, iontophoresis of acetylcholine
36 (ACh) and sodium nitroprusside (SNP), and local hyperthermia. Plasma insulin, leptin, resistin, C-
37 reactive protein, myeloperoxidase (MPO), and tissue plasminogen activator (tPA) were measured.

38 **Results:** At baseline, SOA had similar FMD and impaired NMD in the brachial artery compared to
39 normal-weight adolescents. Similarly, peak responses to ACh and SNP iontophoresis and to local
40 hyperthermia were unaltered whereas cutaneous blood flow following NMD was lower in the forearm
41 microcirculation of SOA. All plasma measurements were significantly higher in SOA. After the program,
42 SOA presented a weight reduction of 7.4 ± 3.1 %, but neither brachial artery nor microvascular reactivity
43 variables were improved. Significant decreases were detected in plasma leptin, MPO and tPA.

44 **Conclusions:** Macro- and microvascular endothelial function are preserved in adolescents with severe
45 obesity. Conversely, a 7 % weight loss does not improve their impaired smooth muscle response to
46 exogenous organic nitrate in both vascular beds, despite reducing plasma markers adversely related to
47 vascular homeostasis.

48

49 Severe obesity in pediatric population is a major public health concern, as well as one of the fastest
50 growing obesity categories in childhood obesity (1), which is associated with vascular risk factors and
51 disease in adulthood (2). Moreover, the progressive exacerbation of preclinical signs of vascular disease
52 might be particularly accelerated in obese adolescents on account of the pro-inflammatory and pro-
53 oxidative changes that occur during puberty, plausibly hampering vascular function (3). The early
54 detection of vascular alterations is thus a major clinical goal to identify subjects at risk for cardiovascular
55 morbidity, and to initiate strategies to reduce risk exposure.

56

57 Endothelial dysfunction is a primary sign of the early stage of atherosclerotic disease, appearing long
58 before the symptoms (4). This alteration has been observed at the macrovascular level in severely obese
59 children and adolescents (5). However, data remain scarce concerning the endothelial function at the
60 microcirculation level in severe childhood obesity (6). The microcirculation, in turn, is increasingly
61 recognized to be independently involved in vascular diseases previously thought to be primarily a
62 macrocirculation matter (7). Furthermore, the specific vascular profile of severely obese pubertal
63 adolescents (SOA) is unknown, since the aforementioned studies included pre-pubertal children (5; 6).

64

65 Although lifestyle interventions, including physical activity and/or diet, result in well-known vascular
66 benefits associated with a decrease in markers of inflammation and oxidative stress in moderately obese
67 children and adolescents (3), their effects remain unknown in severe childhood obesity. Therefore, the
68 aims of the present study were 1) to investigate, in a comprehensive manner, the vascular function in the
69 macro- and microcirculation of severely obese and normal weight adolescents, and 2) to determine the
70 longitudinal effects of a weight loss program on both vascular beds in SOA.

71

72 MATERIALS AND METHODS

73

74 *Subjects*

75 Seventeen adolescents with severe obesity were recruited from a pediatric weight management center.
76 Obesity was defined according to the age and sex-specific cut-off points of childhood obesity as indicated
77 by the International Obesity Task Force (8). BMI z-scores were calculated and values greater than 3
78 defined severe obesity (9). Nineteen healthy normal-weight pubertal stage-matched adolescents were
79 recruited from the community to serve as controls (Table 1). All subjects were normotensive (defined as a
80 pressure < 95th sex-, age-, and height-specific percentiles), non-diabetic, and free from further known
81 obesity-related comorbidities. Exclusion criteria for all subjects included a family history of premature
82 cardiovascular disease, intake of any medication, pubertal status assessed by Tanner stage < 2, weight
83 loss larger than 5% of their total weight during the previous 3 months, and non-sedentary status (> 3 h of
84 exercise per week) to minimize training effects. Informed consent was obtained from the parents and
85 adolescents. The study protocol was approved by the local Ethics Committee and performed in
86 accordance with the principles outlined in the Declaration of Helsinki.

87

88 *Weight loss program*

89 The SOA group underwent a weight loss program consisting in diet and exercise managed by the
90 pediatric weight center. Clinical and vascular assessment of SOA was performed within the first week,
91 and four months later after inclusion in the center. A 4-month period between assessments was considered
92 sufficient time to detect successful weight loss (estimated at 7% of the initial weight) and potential
93 vascular improvement in obese subjects (10). SOA received a moderately hypocaloric diet (reduction of
94 ~300 to 500 calories/day) based on a balanced distribution of carbohydrates (55%), proteins (15%), and
95 lipids (30% total, with less than 10% saturated fat), while performing a physical activity program
96 consisting of four 90-minute supervised sessions per week. Each session mostly involved aerobic
97 exercise, including dancing, tennis, and recreational games, intended to encourage physical activity in the
98 subjects.

99

100 *Vascular measurements*

101 All vascular measurements were performed after fasting overnight in a quiet room with a controlled
102 temperature between 22 and 24 °C. All subjects had abstained from strenuous exercise for 48 h before the
103 test. Measurements commenced after 20 minutes of acclimatization in supine position, and blood
104 pressures were measured on the left arm by an automated system (Dinamap, GE Medical Systems,
105 Milwaukee, USA).

106 Macrovascular assessment of the brachial conduit artery was performed by the same investigator (A.V.),
107 according to the International Brachial Reactivity Task Force Guidelines (11). Brachial measurements
108 were achieved using high-resolution vascular ultrasonography (MyLab30, Esaote SpA, Firenze, Italy),
109 with a 10-MHz multi-frequency linear probe. B-mode images and Doppler signals were continuously and
110 simultaneously recorded for off-line analysis. All results were calculated as the average of 5 consecutive
111 measurements. Flow mediated dilation (FMD), a well-established noninvasive method to estimate
112 endothelial function in conduit artery, was performed. Briefly, a pneumatic cuff was put on the right
113 forearm near the elbow. The ultrasound probe was placed approximately midway between the antecubital
114 and axillary regions, and baseline brachial artery diastolic lumen diameter was measured. The cuff was
115 then inflated to 250 Hg mm for 5 minutes before sudden cuff deflation induced post-ischemic hyperemia.
116 Fifteen minutes later, baseline measurements were repeated before 0.4 mg of isosorbide dinitrate (Isocard,
117 Schwarz Pharma, Monheim, Germany), an endothelium-independent vasodilator, was given sublingually
118 to assess endothelium-independent vasodilation (nitrate-mediated dilation, NMD) . This procedure is
119 described in detail elsewhere (12). FMD and NMD were expressed as the percentage change of peak
120 diastolic brachial diameter after reactive hyperemia and exogenous organic nitrate administration,
121 respectively, relative to the baseline diastolic diameter. Time-averaged mean blood flow velocity and
122 blood flow were determined, as previously described (13). Shear rate (s^{-1}) was calculated as $4 \times$ time-
123 averaged mean blood flow velocity/mean brachial diameter, to estimate resting and peak shear stress (14).
124 FMD was normalized by the net shear rate stimulus (peak minus resting shear rate, Δ shear rate). Although
125 the validity of shear normalization is controversial, we added this measurement as it is commonly used by

126 other researchers. Within-subject coefficient of variations in our laboratory at rest were 1.8% for arterial
127 diameters, 13.2% for time averaged mean velocity and 12.7% for blood flow (13).

128

129 Microvascular assessment of cutaneous blood flow (CBF) was performed by one investigator (D.M.) by
130 means of the laser Doppler flowmetry (LDF) technique. LDF continuously monitors perfusion by
131 measuring microvascular red blood flow using the Doppler principle. The LDF technique has been
132 previously described in detail (15). Cutaneous blood flow (CBF) was measured in conventional perfusion
133 units (PU) using a LDF system (Periflux PF 5000, Perimed, Stockholm, Sweden), equipped with a
134 thermostatic LDF probe with an effective surface of 0.95 cm^2 (PF 481, Perimed, Stockholm, Sweden), on
135 the volar surface of the left forearm. Before commencing the iontophoresis protocol, resting forearm CBF
136 was calculated by averaging a 3-minute steady recording using a non-drug-containing LDF probe. A
137 direct current for drug iontophoresis was provided by a battery-powered current stimulator (Perilont,
138 Perimed, Stockholm, Sweden). Iontophoresis allows non-invasive drug delivery to the skin without
139 systemic effects and perturbation of the skin. Microvascular responses to iontophoresis of acetylcholine
140 (ACh) and sodium nitroprusside (SNP) were assessed. SNP 1% and ACh 1% solutions, adjusted to a
141 physiological ionic strength (0.154 M) by adding saline solution, were administered via two drug delivery
142 electrodes, each inserted within an LDF probe, positioned 10 cm apart avoiding superficial veins and
143 broken epidermal areas. In order to minimize non-specific vasodilatory effects, the iontophoresis protocol
144 consisted in a single anodal (ACh) or cathodal (SNP) pulse of 0.021 mA/cm^2 for 370 s, yielding a total
145 charge of 7.8 mC/cm^2 (16). In addition, a non-drug containing LDF probe determined the CBF response
146 to sublingual administration of organic nitrate (NMD). LDF probes were maintained at a constant
147 temperature of 33°C throughout the whole measuring process. To assess the local hyperthermia response,
148 a non-drug containing LDF probe was heated to 42°C for 5 minutes. Only the plateau phase
149 (endothelium-dependent) of the hyperthermia response was analyzed. Peak CBF responses to ACh, SNP,
150 NMD and local hyperthermia were determined as the maximum average value over a 10 s period within
151 their respective procedures. Concerning the spatial variability of LDF measurements, the specific volar

152 forearm location of each LDF probe and electrode was approximately maintained in all subjects,
153 especially for SOA before and after the weight loss program in which locations were noted in relation to
154 anatomical landmarks.

155

156 *Blood analysis*

157 Blood samples were collected after fasting overnight. Biochemical markers related to vascular function
158 such as leptin, resistin, C-reactive protein (CRP), myeloperoxidase (MPO), and tissue plasminogen
159 activator (tPA) were determined in plasma by bead-based multiplex immunoassays (FlowCytomix,
160 eBioscience, San Diego, CA, USA). Plasma insulin was measured using the radioimmunoassay method
161 (coat-a-count radioimmunoassay kit TKIN2, Siemens, Berlin, Germany).

162

163 *Statistical analysis*

164 All normally distributed variables were expressed as mean \pm SD. Data that were not normally distributed
165 (CRP, tPA, and microvascular variables) were log-transformed to approximate normality before
166 parametric testing, and were expressed as median (interquartile range) in Tables 1 and 3. SOA versus
167 normal-weight subjects were compared by independent *t*-tests and analysis of covariance (ANCOVA),
168 including gender as a covariate. Paired student *t*-tests were used to assess SOA before and after the weight
169 loss program. Bivariate associations between vascular and study variables were determined by calculating
170 Pearson's correlation coefficients. A two-tailed *p*-value less than 0.05 was considered significant. All
171 statistical analyses were performed using MedCalc software (bvba, Mariakerke, Belgium).

172

173 RESULTS

174

175 The major clinical characteristics of the subjects are shown in Table 1. At baseline, SOA presented higher
176 BMI, BMI *z*-score, and waist circumference than normal-weight adolescents. Likewise, SOA showed
177 higher insulin, leptin, resistin, CRP, MPO, and tPA plasma levels (Table 1).

178 With respect to the vascular assessment in the brachial artery, similar FMD values were found between
179 groups, whereas resting blood flow, resting shear rate, and peak shear rate were higher in SOA (Table 2).
180 Normalization of FMD by Δ shear rate yielded similar values between groups. Conversely, SOA presented
181 lower NMD of the brachial artery than normal-weight adolescents (Table 2).

182 In the microcirculation, peak CBF during NMD was also reduced in SOA (Table 3). Resting CBF was
183 lower in SOA, but peak CBF after ACh, SNP iontophoresis and local hyperthermia were unaltered
184 between groups (Table 3). All previous results did not differ when adjusted for gender.

185 Following correlation analysis (Table 4), Δ shear rate was positively associated with BMI ($r = .372$, $P =$
186 $.036$), waist circumference ($r = .366$, $P = .043$), and tPA ($r = .363$, $P = .045$). Significant inverse
187 associations were detected between NMD and adiposity measurements (weight, BMI, BMI z-score, and
188 waist circumference), the strongest being for NMD and waist circumference ($r = -.473$, $P = .006$).
189 Similarly, forearm resting CBF was inversely associated with adiposity measurements, and leptin ($r = -$
190 $.447$, $P = .009$). Negative associations were also detected for forearm peak CBF during NMD with
191 resistin ($r = -.528$, $P = .002$), and MPO ($r = -.381$, $P = .031$) (Table 4).

192
193 After the weight loss program, SOA exhibited a mean weight reduction of 7.4 ± 3.1 %, as well as
194 decreased BMI, BMI z-score, and waist circumference (Table 1). Plasma leptin, MPO and tPA
195 measurements were also significantly reduced in SOA (Table 1). As regards brachial artery variables,
196 resting diameter was increased, while resting shear rate, peak shear rate and Δ shear rate were diminished
197 (Table 2). No significant changes were observed in FMD or NMD (Table 2). Moreover, NMD remained
198 impaired in SOA when adjusted for gender compared to normal-weight adolescents ($P = .038$). In the
199 microcirculation, peak CBF during NMD was further reduced in SOA after the weight loss program,
200 whereas no significant changes were noted in other microvascular variables (Table 3).

201

202 DISCUSSION

203

204 The most important findings in this study are: 1) SOA exhibit preserved endothelial function but impaired
205 smooth muscle response to exogenous organic nitrate in both macro- and microcirculation, and 2) a 4-
206 month weight-loss program does not improve NMD in either of the two vascular beds assessed in SOA,
207 despite of a significant weight loss and decreased plasma levels of selective markers adversely related to
208 vascular function. These findings add new evidence for endothelial function preservation in childhood
209 obesity, which was proposed to be a transitory adaptation to chronic hyperemia. Nevertheless, the absence
210 of improvement in NMD after a 7% weight loss suggests the necessity of longer and/or more intense
211 weight loss programs in SOA.

212

213 Although our finding of preserved FMD in SOA is not universal (5), the present study is in accordance
214 with recent and larger published works comparing obese children and adolescents to their normal-weight
215 counterparts (17-19). Since brachial blood flow at rest and during hyperemia was higher in obese
216 children, Charakida et al. (19) hypothesized that the endothelial function of conduit arteries may be
217 temporarily adapted to the hemodynamic consequences of adiposity, thus partially counteracting the well-
218 known adverse effects of obesity on vascular function. Likewise, we observed that SOA had increased
219 both resting and hyperemic shear rate, which is the primary hemodynamic stimulus to induce endothelial
220 nitric oxide synthase (eNOS) expression (20), probably increasing the endothelium-mediated vasodilatory
221 capacity of SOA. Preserved endothelial function was also observed in the microcirculation via two
222 different stimuli. Peak responses to iontophoresis of ACh and local hyperthermia in the forearm
223 microcirculation were not attenuated in SOA. To our knowledge, no other studies have assessed the
224 microvascular reactivity to ACh and/or local hyperthermia in obese adolescents without co-morbidities.
225 Altogether, these findings support the hypothesis that during childhood there may be intervals in which
226 obese children present a preserved endothelial function in both the macro- and microcirculation. Further
227 research is needed to evaluate whether such intervals of adaptive compensatory endothelial function
228 might imply a progressive or even more accelerated deterioration of vascular function during adulthood
229 (21).

230

231 Unfortunately, previous reports indicating preserved endothelial function in obese children and
232 adolescents (17-19) did not assess smooth muscle function, which is, apart from its intrinsic interest,
233 recommended in order to confirm endothelial function results (11). Our results indicate that the smooth
234 muscle response to exogenous organic nitrate (NMD) is impaired in the brachial artery and the
235 microvasculature of SOA. This NMD impairment in conduit arteries was already described in obese
236 children (22) and adolescents (5; 23; 24), but always in the presence of endothelial dysfunction (impaired
237 FMD). Given that the FMD response includes at least in part the function of the smooth muscle, the
238 unaltered FMD in SOA suggests that there is either normal smooth muscle function at submaximal
239 vasodilation or impaired smooth muscle function at submaximal vasodilation counterbalanced by
240 increased endothelial function, in line with the aforementioned hypothesis (19). Similarly, at
241 microvascular level, endothelial responses (peak CBF after ACh iontophoresis and hyperthermia) were
242 normal, however peak CBF following NMD was decreased in the forearm microcirculation of SOA. In
243 contrast, a similar peak perfusion following SNP iontophoresis was detected in both groups. The reasons
244 explaining the different results of these two nitrodilators are unclear. At first sight, considering that there
245 is an increase of oxidative stress markers in the plasma of SOA, we might speculate that the orally
246 administered organic nitrate (isorbide dinitrate, NMD) underwent a more prolonged exposure to oxidative
247 stress-mediated inactivation than SNP, which was transdermally delivered. However, the fact that the
248 dilator activity of organic nitrates depends on its conversion to nitric oxide (NO) inside the smooth
249 muscle cells (25) weakens this hypothesis. Another potential explanation may be related to the
250 vasodilatory effects inherently associated with the iontophoresis procedure (26). The electric current of
251 iontophoresis could stimulate, to some extent, underlying mechanisms of vasodilation related to the so-
252 called axon reflex (27). Even though we tried to avoid non-specific effects of iontophoresis by reducing
253 the current intensity, we cannot discard the possibility of some effects of SNP iontophoresis being
254 attributed to the axon reflex response. Nevertheless, overall, these findings demonstrated for the first time

255 the proof of a widespread decreased smooth muscle function in SOA compared to normal-weight
256 adolescents.

257

258 Obesity and puberty, characterized by dynamic hormonal and physiological changes in boys and girls,
259 may alter metabolic and vascular homeostasis by promoting a pro-inflammatory and pro-oxidant state (3).
260 Effectively, plasma markers related to adiposity, inflammation, oxidative stress and endothelial activation
261 were altered in SOA. At baseline, SOA presented elevated levels of insulin and leptin, two related
262 hormones with overlapping effects on the hypothalamic control of energy homeostasis (28). Leptin is also
263 associated with increased sympathetic activity (29), which was suggested to be compatible with the lower
264 resting blood flow noticed in obese adults (30). Identically, SOA presented lower CBF at rest than
265 normal-weight counterparts in relation to their higher leptin level (Table 4).

266 In addition, SOA presented higher values of CRP and MPO, suggesting the presence of systemic
267 inflammation (31) and neutrophil-mediated oxidative stress (32), respectively. In correlation analysis,
268 MPO was inversely associated with NMD response in the microcirculation, but not in the brachial artery
269 (Table 4), suggesting a higher vulnerability to oxidative stress-mediated inactivation of NO in the smaller
270 vessels. Moreover, tPA, considered to reflect endothelial activation (33), was augmented in SOA and
271 positively associated to Δ shear rate. Increased vascular shear stress was shown to stimulate tPA
272 expression and secretion by endothelial cells (34), which may explain to some extent the higher plasma
273 levels of tPA found in SOA. Regarding the prognostic significance of these markers, increases in plasma
274 CRP and MPO were recently associated with cardiovascular risk in obese children (35), while high levels
275 of tPA were found to precede the development of type 2 diabetes in a large longitudinal study (36).

276 Furthermore, resistin was increased in SOA as well as negatively associated with peak NMD response in
277 the microcirculation (Table 4). The latter finding could give new clues concerning the controversy on the
278 role of resistin in the pathogenesis of obesity-related comorbidities (37). Otherwise, a 7 % weight loss did
279 not modify the plasma levels of insulin, resistin and CRP in SOA. Nonetheless, the significant reductions

280 in leptin, MPO and tPA after weight loss reinforce the therapeutic effects of hypocaloric diets and
281 physical activity programs in obese subjects.

282

283 The success of the weight loss program in reducing adiposity and plasma markers potentially altering
284 vascular homeostasis in SOA, did not involve beneficial effects on macro- and microvascular function.

285 The impaired NMD in the brachial artery was not significantly enhanced in SOA. To our knowledge, only
286 one prior study evaluated the effect of a non-pharmacological program in obese children presenting
287 impaired NMD (38). Similarly, they reported no significant change in brachial NMD in a randomized
288 controlled trial assessing the effects of 3-month of exercise training in obese children (38). However, that
289 exercise strategy without dietary intervention did not result in any appreciable weight loss, whereas in our
290 study SOA presented a 7 % weight loss, which was previously associated to vascular function
291 improvement in obese subjects (10). One explanation for the lack of enhancement of brachial NMD in our
292 study may be related to the elevated resting brachial shear rate, even after weight loss, observed in SOA.

293 It is conceivable that chronic shear rate-stimulated overexpression of eNOS, thus increasing nitric oxide
294 (NO) release, might lead to some degree of smooth muscle tolerance to NO-mediated vasodilation (39)
295 that was not reversed by the 7% weight loss in SOA. Furthermore, the NMD response was further
296 reduced in the microcirculation of SOA after weight loss. Currently, reasons for such decreased
297 microvascular smooth muscle function are unclear and requires further investigation. Taken together, the
298 outcomes of this study suggest that longer and/or more intense weight loss programs might be needed to
299 restore smooth muscle function in the macro- and microcirculation of SOA.

300

301 There are several limitations to the present study. This is a single-center study with limited sample size
302 and conclusions must be taken with caution. Due to the nature of human research, there are likely to be
303 unrecognized variables leading to residual confounding. For instance, despite the baseline assessment of
304 SOA was performed within the first week after being admitted in the center, we cannot discard the
305 possibility that some SOA anticipated a somewhat control of nutrient intake before their entrance in the

306 center, which might have positively influenced their baseline vascular responses. Furthermore, the
307 cutaneous microcirculation, which we investigated, may raise doubts about its overall significance for
308 vascular risk assessment. However, there is substantial evidence that cutaneous microcirculation is
309 representative of the microcirculation in general. This is underscored by several reports indicating that
310 cutaneous microvascular function mirrors generalized systemic microvascular function (40).

311

312 In summary, we have shown that endothelial function is preserved in the macro- and microcirculation of
313 adolescents with severe obesity. Nevertheless, a 7 % weight loss does not induce an improvement of their
314 impaired smooth muscle response to organic nitrate in whichever vascular bed assessed. Further studies
315 are required to determine whether longer and/or more intense weight loss programs can enhance arterial
316 smooth muscle function in this population.

317

318

319

320

321 **REFERENCES**

322 1. **Skelton J, Cook S, Auinger P, Klein J, Barlow S** 2009 Prevalence and trends of severe obesity
323 among US children and adolescents. *Acad Pediatr* 9:322-329

324 2. **Must A, Jacques P, Dallal G, Bajema C, Dietz W** 1992 Long-term morbidity and mortality of
325 overweight adolescents. A follow-up of the Harvard Growth Study of 1922 to 1935. *N Engl J Med*
326 327:1350-1355

327 3. **Montero D, Walther G, Perez-Martin A, Roche E, Vinet A** 2012 Endothelial dysfunction,
328 inflammation, and oxidative stress in obese children and adolescents: markers and effect of lifestyle
329 intervention. *Obes Rev* 13:441-455

330 4. **Raitakari OT, Celermajer DS** 2000 Flow-mediated dilatation. *Br J Clin Pharmacol* 50:397-404

- 331 5. **Tounian P, Aggoun Y, Dubern B, Varille V, Guy-Grand B, Sidi D, Girardet JP, Bonner D** 2001
332 Presence of increased stiffness of the common carotid artery and endothelial dysfunction in severely
333 obese children: a prospective study. *Lancet* 358:1400-1404
- 334 6. **Schlager O, Willfort-Ehringer A, Hammer A, Steiner S, Fritsch M, Giurgea A, Margeta C, Lilaj**
335 **I, Zehetmayer S, Widhalm K, Koppensteiner R, Gschwandtner ME** 2011 Microvascular function is
336 impaired in children with morbid obesity. *Vasc Med* 16:97-102
- 337 7. **Wiernsperger N, Rapin JR** 2012 Microvascular diseases: is a new era coming? *Cardiovasc Hematol*
338 *Agents Med Chem* 10:167-183
- 339 8. **Cole T, Bellizzi M, Flegal K, Dietz W** 2000 Establishing a standard definition for child overweight
340 and obesity worldwide: international survey. *BMJ* 320:1240-1243
- 341 9. **Rolland-Cachera M, Cole T, Sempe M, Tichet J, Rossignol C, Charraud A** 1991 Body Mass Index
342 variations: centiles from birth to 87 years. *Eur J Clin Nutr* 45:13-21
- 343 10. **Hamdy O, Ledbury S, Mullooly C, Jarema C, Porter S, Ovalle K, Moussa A, Caselli A,**
344 **Caballero AE, Economides PA, Veves A, Horton ES** 2003 Lifestyle modification improves endothelial
345 function in obese subjects with the insulin resistance syndrome. *Diabetes Care* 26:2119-2125
- 346 11. **Corretti M, Anderson T, Benjamin E, Celermajer D, Charbonneau F, Creager M, Deanfield J,**
347 **Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R; International Brachial**
348 **Artery Reactivity Task Force** 2002 Guidelines for the ultrasound assessment of endothelial-dependent
349 flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity
350 Task Force. *J Am Coll Cardiol* 39:257-265
- 351 12. **Karpoff L, Vinet A, Schuster I, Oudot C, Goret L, Dauzat M, Obert P, Perez-Martin A** 2009
352 Abnormal vascular reactivity at rest and exercise in obese boys. *Eur J Clin Invest* 39:94-102
- 353 13. **Walther G, Nottin S, Dauzat M, Obert P** 2006 Femoral and axillary ultrasound blood flow during
354 exercise: a methodological study. *Med Sci Sports Exerc* 38:1353-1361
- 355 14. **Betik AC, Luckham VB, Hughson RL** 2004 Flow-mediated dilation in human brachial artery after
356 different circulatory occlusion conditions. *Am J Physiol Heart Circ Physiol* 286:H442-448

- 357 15. **Leahy MJ, de Mul FF, Nilsson GE, Maniewski R** 1999 Principles and practice of the laser-Doppler
358 perfusion technique. *Technol Health Care* 7:143-162
- 359 16. **Droog EJ, Henricson J, Nilsson GE, Sjoberg F** 2004 A protocol for iontophoresis of acetylcholine
360 and sodium nitroprusside that minimises nonspecific vasodilatory effects. *Microvasc Res* 67:197-202
- 361 17. **Koopman LP, McCrindle BW, Slorach C, Chahal N, Hui W, Sarkola T, Manhiot C, Jaeggi ET,**
362 **Bradley TJ, Mertens L** 2012 Interaction between myocardial and vascular changes in obese children: a
363 pilot study. *J Am Soc Echocardiogr* 25:401-410 e401
- 364 18. **Naylor LH, Green DJ, Jones TW, Kalic RJ, Suriano KL, Shah M, Hopkins N, Davis EA** 2011
365 Endothelial function and carotid intima-medial thickness in adolescents with type 2 diabetes mellitus. *J*
366 *Pediatr* 159:971-974
- 367 19. **Charakida M, Jones A, Falaschetti E, Khan T, Finer N, Sattar N, Hingorani A, Lawlor DA,**
368 **Smith GD, Deanfield JE** 2012 Childhood Obesity and Vascular Phenotypes: A Population Study. *J Am*
369 *Coll Cardiol*; 60(25):2643-2650
- 370 20. **Davis ME, Cai H, Drummond GR, Harrison DG** 2001 Shear stress regulates endothelial nitric
371 oxide synthase expression through c-Src by divergent signaling pathways. *Circ Res* 89:1073-1080
- 372 21. **Zalesin KC, Franklin BA, Miller WM, Peterson ED, McCullough PA** 2008 Impact of obesity on
373 cardiovascular disease. *Endocrinol Metab Clin North Am* 37:663-684
- 374 22. **Aggoun Y, Farpour-Lambert NJ, Marchand LM, Golay E, Maggio AB, Beghetti M** 2008
375 Impaired endothelial and smooth muscle functions and arterial stiffness appear before puberty in obese
376 children and are associated with elevated ambulatory blood pressure. *Eur Heart J* 29:792-799
- 377 23. **Pena AS, Belobrajdic DP, Wiltshire E, Gent R, Hirte C, Couper J** 2010 Adiponectin relates to
378 smooth muscle function and folate in obese children. *Int J Pediatr Obes* 5:185-191
- 379 24. **Pena AS, Wiltshire E, MacKenzie K, Gent R, Piotto L, Hirte C, Couper J** 2006 Vascular
380 endothelial and smooth muscle function relates to body mass index and glucose in obese and nonobese
381 children. *J Clin Endocrinol Metab* 91:4467-4471
- 382 25. **Mehta JL** 1995 Endothelium, coronary vasodilation, and organic nitrates. *Am Heart J* 129:382-391

- 383 26. **Roustit M, Cracowski JL** 2012 Non-invasive assessment of skin microvascular function in humans:
384 an insight into methods. *Microcirculation* 19:47-64
- 385 27. **Durand S, Fromy B, Bouye P, Saumet JL, Abraham P** 2002 Current-induced vasodilation during
386 water iontophoresis (5 min, 0.10 mA) is delayed from current onset and involves aspirin sensitive
387 mechanisms. *J Vasc Res* 39:59-71
- 388 28. **Niswender KD, Schwartz MW** 2003 Insulin and leptin revisited: adiposity signals with overlapping
389 physiological and intracellular signaling capabilities. *Front Neuroendocrinol* 24:1-10
- 390 29. **Monroe MB, Van Pelt RE, Schiller BC, Seals DR, Jones PP** 2000 Relation of leptin and insulin to
391 adiposity-associated elevations in sympathetic activity with age in humans. *Int J Obes Relat Metab Disord*
392 24:1183-1187
- 393 30. **Doupis J, Rahangdale S, Gnardellis C, Pena SE, Malhotra A, Veves A.**2011 Effects of Diabetes
394 and Obesity on Vascular Reactivity, Inflammatory Cytokines, and Growth Factors. *Obesity* 19(4):729-
395 735
- 396 31. **Rocha VZ, Folco EJ** 2011 Inflammatory concepts of obesity. *Int J Inflamm*:529061
- 397 32. **Loria V, Dato I, Graziani F, Biasucci LM** 2008 Myeloperoxidase: a new biomarker of inflammation
398 in ischemic heart disease and acute coronary syndromes. *Mediators Inflamm*: 135625
- 399 33. **Bagg W, Ferri C, Desideri G, Gamble G, Ockelford P, Braatvedt GD** 2001 The influences of
400 obesity and glycemic control on endothelial activation in patients with type 2 diabetes. *J Clin Endocrinol*
401 *Metab* 86:5491-5497
- 402 34. **Diamond SL, Sharefkin JB, Dieffenbach C, Frasier-Scott K, McIntire LV, Eskin SG** 1990 Tissue
403 plasminogen activator messenger RNA levels increase in cultured human endothelial cells exposed to
404 laminar shear stress. *J Cell Physiol* 143:364-371
- 405 35. **Olza J, Aguilera CM, Gil-Campos M, Leis R, Bueno G, Martínez-Jimenez MD, Valle M, Cañete**
406 **R, Tojo R, Moreno LA, Gil A** 2012 Myeloperoxidase is an early biomarker of inflammation and
407 cardiovascular risk in prepubertal obese children. *Diabetes Care* 35:2373-2376

- 408 36. **Eliasson MC, Jansson JH, Lindahl B, Stegmayr B** 2003 High levels of tissue plasminogen activator
409 (tPA) antigen precede the development of type 2 diabetes in a longitudinal population study. The
410 Northern Sweden MONICA study. *Cardiovasc Diabetol* 2:19
- 411 37. **Kusminski CM, McTernan PG, Kumar S** 2005 Role of resistin in obesity, insulin resistance and
412 Type II diabetes. *Clin Sci* 109:243-256
- 413 38. **Farpour-Lambert NJ, Aggoun Y, Marchand LM, Martin XE, Herrmann FR, Beghetti M** 2009
414 Physical activity reduces systemic blood pressure and improves early markers of atherosclerosis in pre-
415 pubertal obese children. *J Am Coll Cardiol* 54:2396-2406
- 416 39. **Yamashita T, Kawashima S, Ohashi Y, Ozaki M, Rikitake Y, Inoue N, Hirata K, Akita H,**
417 **Yokoyama M** 2000 Mechanisms of reduced nitric oxide/cGMP-mediated vasorelaxation in transgenic
418 mice overexpressing endothelial nitric oxide synthase. *Hypertension* 36:97-102
- 419 40. **Holowatz LA, Thompson-Torgerson CS, Kenney WL** 2008 The human cutaneous circulation as a
420 model of generalized microvascular function. *J Appl Physiol* 105:370-372

421 **Table 1** Clinical characteristics and biochemical measurements of normal-weight and severely obese
 422 adolescents before and after a 4-month weight loss program

Characteristics	Controls	SOA	
		Before	After
Girls/boys	11/8	12/5	12/5
Age (years)	15.09 ± 1.32	13.45 ± 1.18*	13.79 ± 1.18† ‡
Pubertal stage (Tanner)	3.50 ± 0.73	3.33 ± 1.13	—
Height (cm)	165.32 ± 9.05	162.71 ± 5.95	163.88 ± 6.18†
Weight (kg)	53.14 ± 9.56	88.65 ± 15.62*	81.91 ± 13.69† ‡
BMI (kg/m ²)	19.32 ± 2.32	33.36 ± 4.86*	30.43 ± 4.42† ‡
BMI z-score	-0.02 ± 1.04	4.22 ± 0.73*	3.46 ± 0.68† ‡
Waist circumference (cm)	68.05 ± 7.32	109.50 ± 14.32*	101.25 ± 13.83† ‡
Heart rate (beats/min)	65.52 ± 10.75	65.50 ± 9.80	63.41 ± 9.74
SBP (mm Hg)	102.84 ± 8.69	98.41 ± 9.44	101.53 ± 7.84
DBP (mm Hg)	60.05 ± 6.72	57.06 ± 6.47	56.24 ± 8.45
Insulin (μU/mL)	3.32 ± 1.47	6.15 ± 4.88*	5.04 ± 2.86‡
Leptin (ng/mL)	17.29 ± 15.41	47.56 ± 27.18*	38.38 ± 21.08† ‡
Resistin (ng/mL)	8.47 ± 1.95	10.69 ± 2.11*	10.63 ± 2.15‡
CRP (μg/mL)	0.10 (0.05-0.37)	1.15 (0.49-4.51)*	0.55 (0.35-2.35)‡
MPO (ng/mL)	27.31 ± 10.69	45.76 ± 19.20*	35.14 ± 11.08† ‡
tPA (ng/mL)	2.25 (1.99-2.73)	3.17 (2.49-4.10)*	2.74 (2.24-3.32)† ‡

423 Values are mean ± SD, except for CRP and tPA which are median (IQR); CRP = C-reactive protein; DBP
 424 = diastolic blood pressure; IQR = interquartile range; MPO = myeloperoxidase; SBP = systolic blood

425 pressure; SD = standard deviation; SOA = severely obese adolescents; tPA = tissue plasminogen
426 activator.

427

428 * Severely obese adolescents before weight loss versus normal-weight: $P < .001$ for age, weight, BMI,
429 BMI z-score, waist circumference, leptin, and CRP; $P = .002$ for MPO; $P = .003$ for resistin; $P = .039$ for
430 insulin; $P = .044$ for tPA.

431 † Severely obese adolescents before versus after weight loss: $P < .001$ for age, height, weight,
432 BMI, BMI z-score, and waist circumference; $P = .014$ for tPA; $P = .016$ for leptin; $P = .020$ for
433 MPO.

434 ‡ Severely obese adolescents after weight loss versus normal-weight: $P < .001$ for weight, BMI,
435 BMI z-score, and waist circumference; $P = .002$ for leptin; $P = .004$ for age, resistin, and CRP; $P =$
436 $.041$ for insulin; $P = .044$ for MPO, and tPA.

Table 2 Macrocirculation in normal-weight and severely obese adolescents before and after a 4-month weight loss program

Variable	Controls	SOA	
		Before	After
Resting brachial artery diameter (mm)	3.13 ± 0.50	2.88 ± 0.55	3.05 ± 0.49†
Resting brachial blood flow (ml min ⁻¹)	42.27 ± 25.65	65.30 ± 28.51*	62.63 ± 32.24‡
Resting brachial shear rate (s ⁻¹)	109.31 ± 47.11	232.05 ± 68.01*	193.49 ± 96.25† ‡
Peak brachial blood flow (ml min ⁻¹)	219.78 ± 80.22	278.17 ± 133.60	251.95 ± 98.27
Peak brachial shear rate (s ⁻¹)	490.06 ± 122.00	744.32 ± 245.00*	570.98 ± 99.32†
Δshear rate (s ⁻¹)	386.63 ± 139.59	511.24 ± 227.54	386.06 ± 87.72†
FMD (%)	8.27 ± 3.27	7.53 ± 2.57	7.92 ± 3.30
FMD/Δshear rate	0.024 ± 0.010	0.018 ± 0.008	0.021 ± 0.013
NMD (%)	24.55 ± 8.04	18.21 ± 5.26*	20.42 ± 5.54

Values are mean ± SD. FMD = flow-mediated dilation; NMD = nitrate-mediated dilation; SOA = severely obese adolescents. Δshear rate means peak brachial shear rate minus resting brachial shear rate.

* Severely obese adolescents before weight loss versus normal-weight: $P < .001$ for resting brachial shear rate; $P = .005$ for peak brachial shear rate; $P = .011$ for NMD; $P = .017$ for resting brachial blood flow.

† Severely obese adolescents before versus after weight loss: $P = .011$ for resting brachial artery diameter, and peak brachial shear rate; $P = .035$ for resting brachial shear rate; $P = .047$ for Δshear rate.

‡ Severely obese adolescents after weight loss versus normal-weight: $P = .004$ for resting brachial shear rate; $P = .046$ for resting brachial blood flow.

Table 3 Microcirculation in normal-weight and severely obese adolescents before and after a 4-month weight loss program

Variable	Controls	SOA	
		Before	After
Forearm resting CBF (PU)	8.69 (6.38-14.20)	6.66 (5.45-7.66)*	6.61 (4.87-7.55)‡
Forearm peak ACh iontophoresis CBF (PU)	63.68 (52.43-84.40)	70.96 (40.67-104.28)	60.37 (51.48-88.49)
Forearm peak hyperthermia CBF (PU)	41.15 (35.40-70.51)	51.45 (33.89-74.01)	43.04 (35.36-51.81)
Forearm peak SNP iontophoresis CBF (PU)	18.96 (10.98-27.04)	20.41 (9.11-38.29)	9.85 (7.52-21.08)
Forearm peak CBF during NMD (PU)	21.54 (15.83-30.67)	13.29 (9.73-17.42)*	9.31 (7.21-12.79)† ‡

Values are median (IQR). ACh = acetylcholine; CBF = cutaneous blood flow; IQR = interquartile range; PU = perfusion units; SNP = sodium nitroprusside; SOA = severely obese adolescents.

* Severely obese adolescents before weight loss versus normal-weight: $P = .014$ for forearm peak CBF during NMD; $P = .019$ for forearm resting CBF.

† Severely obese adolescents before versus after weight loss: $P = .015$ for forearm peak CBF during NMD.

‡ Severely obese adolescents after weight loss versus normal-weight: $P < .001$ for forearm peak CBF during NMD; $P = .008$ for forearm resting CBF.

Table 4 Associations of adiposity and biological measurements with vascular measures in normal-weight and severely obese adolescents before a 4-month weight loss program

Variable	Δ shear rate		Brachial NMD		Forearm resting CBF		Forearm peak CBF during NMD	
	<i>r</i>	<i>P</i>	<i>r</i>	<i>P</i>	<i>r</i>	<i>P</i>	<i>r</i>	<i>P</i>
<i>Adiposity measurements</i>								
Weight	.343	NS	-.458	.006	-.348	.047	-.280	NS
BMI	.372	.036	-.400	.019	-.393	.024	-.342	NS
BMI Z-score	.337	NS	-.428	.012	-.365	.037	-.319	NS
Waist circumference	.366	.043	-.473	.006	-.392	.026	-.266	NS
<i>Biological measurements</i>								
Insulin	.014	NS	-.189	NS	-.171	NS	.203	NS
Leptin	.343	NS	-.146	NS	-.447	.009	-.195	NS
Resistin	.150	NS	-.110	NS	-.254	NS	-.528	.002
CRP	.261	NS	-.162	NS	-.276	NS	-.329	NS
MPO	.048	NS	-.132	NS	-.229	NS	-.381	.031
tPA	.363	.045	-.286	NS	-.142	NS	-.079	NS

CBF = cutaneous blood flow; CRP = C-reactive protein; DBP = diastolic blood pressure; MPO = myeloperoxidase; NMD = nitrate-mediated dilation; tPA = tissue plasminogen activator. Δ shear rate means peak brachial shear rate minus resting brachial shear rate.